Citations

Clear

3030 citation(s) found for "Susan, M".

American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults
Orloff, Lisa A. , Wiseman, Sam M. , Bernet, Victor , Fahey, Thomas J. , Shaha, Ashok R. , Shindo, Maisie L., Stack, Brendan C. , Sunwoo, John B. , Wang, Marilene B. , Bernet, Victor J, Snyder, Susan M.

Mayo Clinic

Thyroid | May 31, 2018 | Volume: 28 | Issue: 7 | Pages: 830-841

10.1089/thy.2017.0309 | PMID 29848235 Get It

Effect of physical activity (PA) before and after diagnosis on overall survival (OS) for patients (pts) with lymphoma.
Feldman, Andew L., Allmer, Cristine, Flowers, Christopher R. , Cohen, Jonathon B. , Thompson, Carrie A. , Ip, Andrew , Pophali, Priyanka A. , Larson, Melissa C. , Rosenthal, Allison , Maurer, Matthew J. , Link, Brian K. , Farooq, Umar , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2018 | Volume: 36 | Issue: 7_suppl | Pages: 95-95

10.1200/jco.2018.36.7_suppl.95 Get It

95 Background: While PA is known to improve quality of life in lymphoma pts, its impact on OS is not known. We studied the effect of PA on OS in lymphoma pts enrolled at diagnosis in the Iowa/Mayo Molecular Epidemiology Resource. Methods: Godin Leisure Score Index (LSI; Range 0-50) was calculated based on level of PA pre-diagnosis (baseline) and 3 years post diagnosis (FU3), with pts grouped by tertile into high, moderate, or low PA. At FU3, pts also reported perceived change in PA since diagnosis. OS was measured as time from assessment (baseline or FU3) until death from any cause. Associations between LSI tertiles and OS were assessed using Cox models adjusted for lymphoma subtype, age and sex. Results: PA level was available for 3060 pts at baseline and 1371 pts at FU3. 95% had an ECOG performance status < 2, 37% had an aggressive subtype, 29% had BMI ≥ 30, and 54% were age > 60. Indolent lymphoma pts with higher PA at baseline had no difference in OS. Higher PA at FU3 had improved OS (moderate vs low HR 0.63, CI 0.42-0.93; high vs low HR 0.53, CI 0.33-0.86). Pts with BMI < 30 who had higher PA at baseline showed no difference in OS. Higher PA at FU3 had improved OS for pts with BMI < 30 (moderate vs low HR 0.68 CI, 0.48-0.98; high vs low HR = 0.41, CI 0.26-0.64). For pts > 60 years, high vs low baseline PA showed improved OS (HR 0.77, CI 0.63-0.93). Higher PA at FU3 (moderate vs low HR 0.68 CI 0.48-0.96, high vs low HR 0.53 CI 0.34-0.83) was associated with OS. At FU3, compared to no change, perceived reduction of PA was associated with worse OS for indolent lymphoma (HR 2.13, CI 1.56-2.91), BMI < 30 (HR 1.95, CI 1.45-2.62), BMI > 30 (HR 2.00, CI 1.21-3.30), age ≤ 60 (HR 3.06, CI 1.72-5.46), and age > 60 (HR 1.98, CI 1.52-2.58). Perceived increase in PA was not associated with OS. Higher PA in pts with aggressive lymphoma, BMI ≥30, and age < 60 was not significantly associated with OS but trended similarly. All results were similar when analyzing by continuous LSI score. Conclusions: Higher levels of PA, especially at FU3, were associated with superior OS. The effect was more pronounced in pts with indolent lymphoma, BMI < 30, or age > 60. Perceived reduction in PA was associated with worse outcomes. PA should be incorporated into lymphoma survivorship plans.
Human Pegivirus infection and lymphoma risk and prognosis: a North American study
Famà, Angelo , Xiang, Jinhua , Link, Brian K. , Allmer, Cristine, Klinzman, Donna, Feldman, Andrew L. , Nowakowski, Grzegorz S. , Liebow, Mark , Maurer, Matthew J. , Ansell, Stephen M. , Novak, Anne J. , Asmann, Yan W. , Call, Timothy G. , Stapleton, Jack T. , Maurer, Matthew , Cerhan, James R , Feldman, Andrew L , Link, Brian K , Larson, Melissa C. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

British Journal of Haematology | May 29, 2018 | Volume: 182 | Issue: 5 | Pages: 644-653

10.1111/bjh.15416 | PMID 29808922 Get It

SummaryWe evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of co‐infection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency‐matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT‐PCR), and those with RNA concentrations <5000 genome equivalents/ml were confirmed using nested RT‐PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case‐control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2·14; 95% confidence interval [CI] 1·63–2·80; P < 0·0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event‐free survival (Hazard ratio [HR] = 1·00; 95% CI 0·85–1·18) or overall survival (HR = 0·97; 95% CI 0·79–1·20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.
Value-Added Activities in Medical Education: A Multisite Survey of First- and Second-Year Medical Students’ Perceptions and Factors Influencing Their Potential Engagement
Starr, Stephanie R. , Gonzalo, Jed D. , George, Paul , Miller, Bonnie M. , Morgan, Helen , Hoffman, Ari, Baxley, Elizabeth G., Allen, Bradley L. , Fancher, Tonya L. , Mandrekar, Jay , Skochelak, Susan E., Reed, Darcy A. , Leep Hunderfund, Andrea N, Fancher, Tonya L , Hunderfund, Andrea N. Leep , Dyrbye, Liselotte N.

Mayo Clinic

Academic Medicine | May 23, 2018 | Volume: 93 | Issue: 10 | Pages: 1560-1568

10.1097/acm.0000000000002299 | PMID 29794526 Get It

Purpose To describe attitudes of first- and second-year U.S. medical students toward value-added medical education, assess their self-reported desire to participate in value-added activities, and identify potentially modifiable factors influencing their engagement. Method The authors conducted a cross-sectional survey of first- and second-year students at nine U.S. medical schools in 2017. Survey items measured students’ attitudes toward value-added medical education (n = 7), desire to participate in value-added activities (n = 20), and factors influencing potential engagement (n = 18). Results Of 2,670 students invited to participate, 1,372 (51%) responded. Seventy-six percent (1,043/1,368) moderately or strongly agreed they should make meaningful contributions to patient care. Students’ desire to participate was highest for patient care activities approximating those traditionally performed by physicians, followed by systems improvement activities and lowest for activities not typically performed by physicians. Factors increasing desire to participate included opportunities to interact with practicing physicians (1,182/1,244; 95%), patients (1,177/1,246; 95%), and residents or fellows (1,166/1,246; 94%). Factors decreasing desire to participate included making changes to the health care system (365/1,227; 30%), interacting with patients via phone or electronic communication (410/1,243; 33%), and lack of curricular time (634/1,233; 51%). Conclusions First- and second-year medical students agree they should add value to patient care, but their desire to participate in value-added activities varies depending on the nature of the tasks. Medical schools may be able to increase students’ desire to participate by enabling face-to-face interactions with patients, embedding students in health care teams, and providing dedicated curricular time.
Perceived Social Isolation and Outcomes in Patients With Heart Failure
Manemann, Sheila M., Chamberlain, Alanna M. , Roger, Véronique L. , Boyd, Cynthia M. , Jensen, Daniel R. , Weston, Susan A., Fabbri, Matteo, Jiang, Ruoxiang , Griffin, Joan M. , Finney Rutten, Lila J, Chamberlain, Alanna M , Cudjoe, Thomas , Rutten, Lila J. Finney

Mayo Clinic

Journal of the American Heart Association | May 23, 2018 | Volume: 7 | Issue: 11 | Pages: No page available

10.1161/jaha.117.008069 | PMID 29794038 Get It

Background Perceived social isolation has been shown to have a negative impact on health outcomes, particularly among older adults. However, these relationships have not been fully examined among patients with heart failure. Methods and Results Residents from 11 southeast Minnesota counties with a first‐ever International Classification of Diseases, Ninth Revision ( ICD‐9 ) code 428 for heart failure between January 1, 2013, and March 31, 2015 (N=3867), were prospectively surveyed to measure perceived social isolation. A total of 2003 patients returned the survey (response rate, 52%); 1681 patients completed all questions and were retained for analysis. Among these patients (53% men; mean age, 73 years), ≈19% (n=312) had moderate perceived social isolation and 6% (n=108) had high perceived social isolation. After adjustment, patients reporting moderate perceived social isolation did not have an increased risk of death, hospitalizations, or emergency department visits compared with patients reporting low perceived social isolation; however, patients reporting high perceived social isolation had >3.5 times increased risk of death (hazard ratio, 3.74; 95% confidence interval [ CI ], 1.82–7.70), 68% increased risk of hospitalization (hazard ratio, 1.68; 95% CI , 1.18–2.39), and 57% increased risk of emergency department visits (hazard ratio, 1.57; 95% CI , 1.09–2.27). Compared with patients who self‐reported low perceived social isolation, patients reporting moderate perceived social isolation had a 16% increased risk of outpatient visits (rate ratio, 1.16; 95% CI , 1.03–1.31), whereas those reporting high perceived social isolation had a 26% increased risk (rate ratio, 1.26; 95% CI , 1.04–1.53). Conclusions In patients with heart failure, greater perceived social isolation is associated with an increased risk of death and healthcare use. Assessing perceived social isolation during the clinical encounter with a brief screening tool may help identify patients with heart failure at greater risk of poor outcomes.
Axis II Personality Disorders Are Linked to an Adverse Course of Bipolar Disorder
Post, Robert M. , Kupka, Ralph , Suppes, Trisha, Hellemann, Gerhard , Nolen, Willem A. , Frye, Mark A. , Keck, Paul E., Grunze, Heinz , Frye, Mark, Grunze, Heinz , McElroy, Susan L. , Rowe, Michael J.

Mayo Clinic

Journal of Nervous & Mental Disease | May 17, 2018 | Volume: 206 | Issue: 6 | Pages: 469-472

10.1097/nmd.0000000000000819 | PMID 29781886 Get It

Abstract The relationship of personality disorder (PD) psychopathology to the course of bipolar disorder remains inadequately described. After giving informed consent, more than 782 outpatients with bipolar disorder rated themselves on the 99-item Personality Disorder Questionnaire, Version 4 (PDQ4) when depressed or euthymic. They also rated six poor prognosis factors (PPFs). The relationships of the PPFs to the total PDQ4 score were examined by a linear regression. Even after correcting for the higher PDQ4 scores observed when patients were suffering depression, the PDQ4 was significantly related to a history of child abuse, early age of onset, an anxiety disorder comorbidity, rapid cycling, and 20 or more previous episodes, but not substance abuse. The data suggest close relationships between the total burden of PD psychopathology and correlates of an adverse outcome of bipolar disorder. The nature of this of association and approaches to treatment of comorbid PD remain to be further explored.
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, Rachna T. , Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Rolfe, Lindsey, Goble, Sandra, Giordano, Heidi, Vonderheide, Robert H. , Lin, Kevin K. , McWilliams, Robert R. , Lin, Kevin , Biankin, Andrew V. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | May 16, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-15

10.1200/po.17.00316 | PMID 30051098 Get It

Purpose Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 ( BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in BRCA1/2-mutant pancreatic cancer. Patients and Methods RUCAPANC enrolled patients with measurable locally advanced/metastatic pancreatic cancer who had received one to two prior chemotherapy regimens. Patients received oral rucaparib (600 mg twice daily) until disease progression. The primary end point was objective response rate. Results Nineteen patients were enrolled. Sixteen of 19 BRCA1/2 mutations were germline; three were somatic. Patients had received a median of two prior chemotherapy regimens. Four patients achieved a response; two partial responses and one complete response (CR) were confirmed (objective response rate, 15.8%; 3 of 19), with an additional CR unconfirmed. The disease control rate (CR, partial response, or stable disease for ≥ 12 weeks) was 31.6% (6 of 19) in all patients and 44.4% (4 of 9) in those who had received one prior chemotherapy regimen. As prespecified in the protocol, enrollment was stopped because of an insufficient response rate among the first 15 patients. Treatment-emergent adverse events included nausea (63.2%) and anemia (47.4%). Grade ≥ 3 adverse events included anemia (31.6%), fatigue (15.8%), and ascites (15.8%). Secondary resistance mutations were detected in circulating free tumor DNA in two patients with a germline BRCA2 mutation. These mutations are predicted to lead to the reversion of a somatic—not germline—mutation. Conclusion Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile. Additional trials of rucaparib in this population are warranted.
Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 Diabetes
Rianon, Nahid , Smith, Scott M. , Lee, MinJae , Pervin, Hannah, Musgrave, Paul W., Watt, Gordon P. , Nader, Shahla, McCormick, Joseph B. , Fisher‐Hoch, Susan P. , Rianon, Nahid J , Khosla, Sundeep , Ambrose, Catherine Glauber

Mayo Clinic

Journal of Osteoporosis | May 13, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/7153021 | PMID 29862008 Get It

Altered bone quality, caused by underlying metabolic changes of type 2 diabetes (T2D), has been hypothesized to cause altered bone strength and turnover leading to increased fracture risk in T2D patients. Current understanding about changes in bone turnover markers in T2D patients is mainly based on studies focused on Caucasian men and women. However, Hispanic populations have the highest prevalence of both T2D and osteoporosis in the US. We investigated associations of glycemic control (in terms of glycated hemoglobin [HbA1c]) and bone turnover rate in 69 older (≥50 years) Mexican American Cameron County Hispanic Cohort (CCHC) participants with T2D. Multivariable analyses were conducted to assess the associations between HbA1c (%), serum osteocalcin (OC), and serum sclerostin. In agreement with published reports from other racial/ethnic populations, our study found that lower bone turnover (indicated by lower serum OC) occurred in Mexican American men with T2D who had poorer glycemic control. For the women in our study, we found no significant association between glycemic control and OC. In contrast, HbA1c was positively associated with sclerostin for women, with near significance (p=0.07), while no association was found in men. We recommend screening Mexican American individuals with T2D, specifically those with poor glycemic control, for bone loss and fracture risk.
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
Wang, Sophia , Carrington, Mary , Berndt, Sonja I. , Bracci, Paige M. , Smedby, Karin E. , Hjalgrim, Henrik , Vijai, Joseph , Morton, Lindsay M. , Vermeulen, Roel , Paltiel, Ora , Vajdic, Claire M. , Linet, Martha S. , Nieters, Alexandra , Sanjosé, Sílvia de, Brown, Elizabeth E. , Turner, Jennifer , Spinelli, John J., Zheng, Tongzhang, Birmann, Brenda M. , Flowers, Christopher R. , Becker, Nikolaus, Holly, Elizabeth A., Kane, Eleanor , Weisenburger, Dennis D. , Cocco, Pierluigi, Weinstein, Stephanie J. , Diver, W. Ryan , Lax, S. , Travis, Ruth C., Kaaks, Rudolph, Ríboli, Elio , Benavente, Yolanda , Brennan, Paul, McKay, James , Delfau‐Larue, Marie‐Hélène , Link, Brian K. , Magnani, Corrado , Latte, Giancarlo, Doo, Nicole Wong , Offit, Kenneth , Musinsky, Jacob, Arslan, Alan A. , Purdue, Mark P. , Adami, Hans‐Olov , Melbye, Mads , Glimelius, Bengt , Conde, Lucía , Camp, Nicola J. , Glenn, Martha, Curtin, Karen , Clavel, Jacqueline , Monnereau, Alain, Cox, David G. , Ghesquières, Hervé , Salles, Gilles , Bofetta, Paulo, Foretová, Lenka , Staines, Anthony , Davis, S. Scott , Severson, Richard K., Lan, Qing , Brooks‐Wilson, Angela , Smith, Martyn T. , Roman, Eve , Kricker, Anne , Zhang, Yawei , Kraft, Peter , Rothman, Nathaniel , Hartge, Patricia, Skibola, Christine F., Cocco, Pierluigi , Travis, Ruth C. , Monnereau, Alain , Turner, Jennifer , Weinstein, Stephanie J , Link, Brian K , Joseph, Vijai , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , Kraft, Peter , Morton, Lindsay M , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Riboli, Elio , Slager, Susan L. , Voutsinas, Jenna M. , Cerhan, James R. , Cozen, Wendy , Maynadié, Marc , Albanes, Demetrius , Teras, Lauren R. , Ennas, Maria Grazia , Feldman, Andrew L. , Giles, Graham G. , Southey, Melissa C. , Milne, Roger L. , Chanock, Stephen Jacob , Doo, Nicole Wong

Mayo Clinic

Cancer Research | May 7, 2018 | Volume: 78 | Issue: 14 | Pages: 4086-4096

10.1158/0008-5472.can-17-2900 | PMID 29735552 Get It

Abstract A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06–1.60; OR MZL = 1.45, 95% CI = 1.12–1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24–3.55; OR MZL = 2.10, 95% CI = 0.99–4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend &lt; 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086–96. ©2018 AACR.